Proveca Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 32
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $5.07M
Latest Deal Amount
  • Investors
  • 5

Proveca General Information

Description

Developer of pediatric therapies designed to provide improved children's medicines. The company's medicines are focused on curing medical issues related to neurology, cardiology and analgesia in children, thereby enabling doctors to access the medication for children in an appropriate format and per requirements.

Contact Information

Website
www.proveca.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Pharmaceuticals
Primary Office
  • Wework, Number 1 Spinningfields
  • Quay Street
  • Manchester M3 3JE
  • England, United Kingdom
+44 0161 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Proveca Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 14-Mar-2017 $5.07M 00.00 000.00 Completed Generating Revenue
4. Later Stage VC 01-Aug-2016 00.000 Completed Generating Revenue
3. Grant 00000 00.000 Completed Generating Revenue
2. Grant 01-Aug-2013 $4.18M Completed Generating Revenue
1. Early Stage VC 20-Dec-2012 $4.18M $4.18M Completed Generating Revenue
To view Proveca’s complete valuation and funding history, request access »

Proveca Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
G Ordinary 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
F Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.00
Ordinary 0,000 00.000000 000.00 000.00 00 000.00 0.000
E Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
E Ordinary 00,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary 00,000 00.000000 00.00 00.00 00 00.00 0.000
D Ordinary 43,321 $0.001235 $8.23 $8.23 1x $8.23 14.69%
D Ordinary 25,993 $0.001235 $8.23 $8.23 1x $8.23 8.82%
To view Proveca’s complete cap table history, request access »

Proveca Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of pediatric therapies designed to provide improved children's medicines. The company's medicines are focused
Drug Discovery
Manchester, United Kingdom
32 As of 2021
00.00
00.00 0000-00-00
0000000000 0 00.00

00000000

ng elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000 000000000
Paris, France
0 As of 0000
000000000000

00000000

consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000 00000000
Nimes, France
00 As of 0000
000.00
0000 0000-00-00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Proveca Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Orphelia Pharma Accelerator/Incubator Backed Paris, France 0 000000000000
000000000 Formerly VC-backed Nimes, France 00 000.00 00000000 000.00
00000 000000000000 Venture Capital-Backed Waltham, MA 00 000.00 00000000000 000.00
You’re viewing 3 of 3 competitors. Get the full list »

Proveca Executive Team (5)

Name Title Board Seat Contact Info
Simon Bryson Ph.D Co-Founder, Chief Executive Officer & Board Member
Andrew Jackson Chief Financial Officer & Board Member
Helen Shaw Co-Founder, Medical Director & Board Member
Simon Barter Chief Commercial Officer & Board Member
Clare Gleeson Project & Programme Manager
To view Proveca’s complete executive team members history, request access »

Proveca Board Members (8)

Name Representing Role Since
Andrew Jackson Proveca Chief Financial Officer & Board Member 000 0000
Chris Church Self Board Member 000 0000
Christoph Ruedig Albion Capital Board Member 000 0000
Christopher Brinsmead Bamburgh Capital Chairman 000 0000
Gareth King Ph.D Catapult Ventures Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Proveca Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Proveca Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Catapult Ventures Venture Capital Minority 000 0000 000000 0
Kreos Capital Lender/Debt Provider Minority 000 0000 000000 0
Medical Research Council Corporation 000 0000 000000 0
AlbionVC Venture Capital Minority 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
To view Proveca’s complete investors history, request access »